The e TuBer erculos culosis is Vacc ccin ine e Init itia - PowerPoint PPT Presentation

The e TuBer erculos culosis is Vacc ccin ine e Init itia iativ ive e (TBVI) Research and Innovation partnership to discover and develop new, safe and effective TB vaccines that are accessible and affordable for all people Non-profit foundation that creates an enabling environment for TB vaccine research and innovation  TBVI and its R&D partners develop and move the most promising TB vaccine and biomarker candidates through the pipeline.  TBVI supports collaborative research to innovate and diversify the pipeline and TB vaccine platforms. TBVI adds value by providing services:  technical advice through Product and Clinical development teams  project identification, development and management;  resource mobilisation TBVI works through the Global TB Vaccine Partnership (GTBVP) with global stakeholders to:  strengthen Global and European cooperation and coordination  identify and address gaps to move the field forward.

TBVI operating principles To select/down select vaccine candidates in an objective and transparent manner and to use the available financial resources effectively:  TBVI assesses and manages its portfolio based on criteria in its TB Vaccine Development Pathway tool.  It seeks to align its R&I activities with other global efforts, in particular with partners in the Global TB Vaccine Partnership (GTBVP).  TBVI and its R&D partners have developed over 50% of the current candidates in the TB vaccine pipeline To act as a neutral and honest broker  Ownership of vaccine candidates and biomarkers, and any intellectual property rights remain with researchers and vaccine developers  enables TBVI to act as a neutral party without conflict of interest among its R&D partners, global stakeholders and funders. • D through partnership is the philosophy and spirit of TBVI’s collaborative research efforts. The TBVI R&D strategic directions and priorities are based on the scientific and strategic inputs of

20 years of continued R&I work

TBVI : highlights of areas of work/funding needs 2020-2021 Product development  move current leading TB vaccine candidates and fast followers through the pipeline Collaborative research and innovation  innovate and diversify the TB vaccine and biomarker pipeline and TB vaccine platforms  develop and test alternative vaccine routes and delivery mechanisms  develop and validate pre-clinical models; develop human challenge models  develop next generation portfolio management tools; harness the power of AI for TB vaccine and biomarker research and clinical trials Global and European Cooperation and Coordination  continue to build European excellence and leadership in TB vaccine R&D  strengthen and grow GTBVP